A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli) in Healthy Female Subjects Aged 18 to 25 Years

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli) in Healthy Female Subjects Aged 18 to 25 Years

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary) ; Hepatitis B vaccine recombinant
  • Indications Cervical cancer; Hepatitis B; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 21 Feb 2014 Planned End Date changed from 1 Dec 2011 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 21 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top